The Benign Infantile Epilepsy Gene Panel by NGS is a focused molecular test designed to detect genetic variants associated with benign infantile seizures. Metropolis Healthcare performs this analysis using advanced next-generation sequencing to evaluate key epilepsy-related genes with high sensitivity. This test helps confirm diagnosis, differentiate benign syndromes from other epileptic conditions, and guide long-term management. It is especially useful when infants present with early-onset seizures and normal development.
Price:
Rs. 21,000.00
Sample Type: EDTA BLOOD
Fasting Not Required
Notes:G0170
Frequently Asked Questions (FAQ's):
What does this test include at Metropolis Healthcare?
It includes NGS-based sequencing of genes known to cause benign infantile epilepsy and related seizure disorders.
How does Metropolis Healthcare perform this test?
DNA from an EDTA blood sample is analyzed using high-precision next-generation sequencing to detect relevant genetic variants.
Who should take this test at Metropolis Healthcare?
Infants with unexplained seizures, normal neurological development, or a family history of benign infantile epilepsy.
What sample is required at Metropolis Healthcare?
A routine EDTA blood sample is needed for DNA extraction and sequencing.
How does this test help clinicians at Metropolis Healthcare?
It confirms the genetic cause, assists in prognosis, and helps differentiate benign syndromes from more severe epileptic conditions.
Is any preparation needed before giving the sample at Metropolis Healthcare?
No fasting or special preparation is required for this test.
How long does the test take at Metropolis Healthcare?
Turnaround time usually ranges from several days to a few weeks, depending on sequencing complexity.
When will I receive the report from Metropolis Healthcare?
Reports are provided according to the molecular diagnostics schedule, with expert interpretation included.